Replies to post #125437 on Biotech Values

[biomaven0]

If Teva was bullish on tL's approval prospects, why would Bill Marth make a substantial shift in his commentary from very bullish (FDA approval soon, by year-end, etc.) to the current we have nothing to say.

My take is that Teva's behavior is consistent with them being blindsided by the FDA on some issue - they were indeed expecting approval and then something happened. At that point, if they take the viewpoint that what happened once could happen again, then keeping quiet is the smart thing to do now matter how optimistic they are.

But really I'm not going to further attempt to read the Teva tea leaves here. My basic point is that the risk-reward on MNTA is steadily improving here with their cash position and the increased royalty rate.

Peter